OneSource Pharma adds RPT details to AGM notice for Sept 23 meeting

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • OneSource Specialty Pharma issued an addendum to its 19th AGM notice dated July 24, 2026
  • Additional disclosures relate to RPTs with Strides Pharma Science Limited and its US subsidiary
  • Audit Committee reviewed CEO/CFO certificates as per Industry Standards for RPTs
  • The 19th AGM is scheduled for September 23, 2026, via Video Conferencing
powered bylight_fuzz_icon
50676391

*this image is generated using AI for illustrative purposes only.

OneSource Specialty Pharma issued an addendum to the notice of its 19th Annual General Meeting scheduled for September 23, 2026. The company disclosed additional information regarding material related party transactions with Strides Pharma Science Limited and Strides Pharma Inc, USA.

The addendum forms an integral part of the original AGM notice dated July 24, 2026. It specifically addresses Item No. 6 and Item No. 7 of the agenda, which seek shareholder approval for these transactions. Strides Pharma Inc is a wholly owned subsidiary of Strides Pharma Science Limited.

Compliance Disclosures

The Audit Committee has reviewed the certificates provided by the Chief Executive Officer and Chief Financial Officer of the listed entity. These reviews were conducted in accordance with Industry Standards pertaining to Related Party Transactions (RPTs).

The meeting will be held via Video Conferencing at 5:00 pm IST. The company uploaded the addendum to its website and submitted it to BSE Limited and National Stock Exchange of India Limited for records.

Historical Stock Returns for Onesource Specialty Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+0.27%+0.44%+3.69%+8.67%-14.02%-6.48%

What specific strategic synergies or cost-saving measures does OneSource anticipate from these related party transactions with Strides Pharma?

How might the approval of these transactions influence OneSource's future capital allocation and R&D investment priorities?

Are there potential regulatory hurdles or antitrust concerns associated with the deepening ties between OneSource and Strides Pharma Science Limited?

Onesource Specialty Pharma
View Company Insights
View All News
like15
dislike

OneSource Specialty Pharma files FY26 BRSR report with zero liquid discharge

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • OneSource Specialty Pharma filed its FY26 BRSR report disclosing ₹14,204 million standalone turnover
  • Renewable energy consumption rose to 1,13,219 GJ while non-renewable fuel use dropped significantly
  • Company achieved zero liquid discharge with no external water release from manufacturing units
  • Permanent employee turnover declined to 23% from 27% in the prior fiscal year
  • SGS India provided reasonable assurance on core sustainability indicators
powered bylight_fuzz_icon
49742776

*this image is generated using AI for illustrative purposes only.

OneSource Specialty Pharma has submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing, dated August 31, 2026, discloses key sustainability metrics including energy consumption, water management, and waste handling across its operations.

The company reported a standalone turnover of ₹14,204 million and a net worth of ₹59,430.95 million. Its workforce comprises 1,200 permanent employees and 1,089 workers. Exports accounted for 70.80% of total turnover, serving customers in over 30 countries.

Environmental Metrics

OneSource Specialty Pharma highlighted significant strides in resource efficiency and emission control during FY26.

Metric FY26 FY25
Total Energy Consumed (GJ) 1,40,062.83 1,55,680
Renewable Energy Share (%) 80.83% 71.00%
Total Water Withdrawal (KL) 2,55,733.71 2,12,667.1
Scope 1 + 2 GHG Emissions (MT CO2e) 14,836.46 12,672.7

The entity achieved zero liquid discharge across all manufacturing units, with no water discharged outside premises. Renewable energy consumption rose to 1,13,219.09 GJ, up from 1,10,514 GJ in the prior year. Conversely, non-renewable fuel consumption dropped sharply to 2,802.30 GJ from 20,279 GJ in FY25.

Waste and Circular Economy

Total waste generated increased to 838.114 metric tonnes from 738 metric tonnes in FY25. However, recycling efforts intensified, with 541.69 metric tonnes recovered through recycling, compared to 481.64 metric tonnes previously. Hazardous waste constituted a significant portion, with other hazardous waste rising to 269.695 metric tonnes.

Social and Governance Highlights

The company reported a permanent employee turnover rate of 23% in FY26, down from 27% in FY25. Women constitute 15% of permanent employees and 13% of the Board of Directors. No safety-related incidents, including lost-time injuries or fatalities, were recorded for employees or workers.

SGS India Private Limited provided reasonable assurance on the core indicators of the BRSR report, confirming data accuracy and compliance with SEBI regulations.

Historical Stock Returns for Onesource Specialty Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+0.27%+0.44%+3.69%+8.67%-14.02%-6.48%

How might the increase in Scope 1 and 2 GHG emissions despite higher renewable energy adoption impact OneSource's carbon credit liabilities or ESG ratings in FY27?

What strategic initiatives is OneSource planning to implement to reverse the upward trend in total water withdrawal and hazardous waste generation?

Could the 23% employee turnover rate pose risks to operational continuity or institutional knowledge retention in the specialty pharma sector?

Onesource Specialty Pharma
View Company Insights
View All News
like19
dislike

More News on Onesource Specialty Pharma

1 Year Returns:-14.02%